RECOMBINANT ALBUMIN FUSION PROTEINS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 170

relevance to immunology and medicine. Trends Immunol. 27,
343-348.
8. Chaudhury C, Mehnaz S, Robinson JM, HaytonWL, Pearl DK,
Roopenian DC, et al. (2003) The major histocompatibility
complex-related Fc receptor for IgG (FcRn) binds albumin and
prolongs its lifespan. J. Exp. Med. 197, 315-322.
9. Chemmanur AT, Wu GY. (2006) Drug evaluation: albuferon-
alpha—an antiviral interferon-alpha/albumin fusion protein.
Curr. Opin. Invest. Drugs 7, 750-758.
10. Schulte, S. (2008) Use of albumin fusion technology to prolong
the half-life of

recombinant human albumin induces prolonged myelopoietic
effects in mice and monkeys. Pharmaceut. Res. 19, 1720-
1729.
22. Tomkin GH. (2009) Albiglutide, an albumin-based fusion of
glucagon-like peptide 1 for the potential treatment of type 2
diabetes. Curr. Opin. Mol. Therap. 11, 579-588.
23. Baggio LL, Huang Q, Brown TJ, Drucker DJ. (2004) A
recombinant human glucagon-like peptide (GLP)-1-albumin
protein (albugon) mimics peptidergic activation of GLP-1
receptor-dependent pathways coupled with satiety, gastro-
intestinal motility, and glucose homeostasis. Diabetes 53,
2492-2500.
24. Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge
RJ, Walker SE, et al. (2008) Pharmacodynamics, pharmaco-
kinetics, safety, and tolerability of albiglutide, a long-acting
glucagon-like peptide-1 mimetic, in patients with type 2 diabe-
tes. J. Clin. Endocrinol. Metab. 93, 4810-4817.
25. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chanda-
mouli V, et al. (2004) One week's treatment with the long-
acting glucagon-like peptide 1 derivative liraglutide (NN2211)
markedly improves 24-h glycemia and a - and b -cell function
and reduces endogenous glucose release in patients with type 2
diabetes. Diabetes 53, 1187-1194.
26. Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ,
Neumann AU, et al. (2006) A phase 2 study to evaluate the
antiviral activity, safety, and pharmacokinetics of recombinant
human albumin-interferon alfa fusion protein in genotype 1
chronic hepatitis C patients. J. Hepatol. 44, 671-678.
27. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-
Torres M, Bacon BR, et al. (2010) Albinterfeon alfa-2b was not
inferior to pegylated interferon- a in a randomized trial of
patients with chronic hepatitis C virus genotype 1. Gastroen-
terology 139, 1257-1266.
28. Wang W, Ou Y, Shi, Y. (2004) AlbuBNP, a recombinant B-type
natriuretic peptide and human serum albumin fusion hormone,
as a long-term therapy of congestive heart failure. Pharma-
ceut. Res. 21, 2105-2111.
29. Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B, Chen
G, et al. (2002) Albutropin 1 : a growth hormone-albumin
fusion with improved pharmacokinetics and pharmaco-
dynamics in rats and monkeys. Eur. J. Pharmacol. 456,
149-158.
30. Yao Z, Dai W, Perry J, Brechbiel MW, Sung C. (2004) Effect of
albumin fusion on the biodistribution of interleukin-2. Cancer
Immunol. Immunother. 53, 404-410.
31. Melder RJ, Osborn BL, Riccobene T, Kanakaraj P, Wei P, Chen
G, et al. (2005) Pharmacokinetics and in vitro and in vivo anti-
tumor response of an interleukin-2-human serum albumin
fusion protein in mice. Cancer Immunol. Immunother. 54,
535-547.
32. Evans L, Hughes M, Waters J, Cameron J, Dodsworth N, Tooth
D, et al. (2010) The production, characterization and enhanced
pharmacokinetics of scFv-albumin fusions expressed in Sac-
charomyces cerevisiae. Protein Expr. Purif. 73, 113-124.
33. Marques JA, George JK, Smith IJ, Bhakta V, Sheffield WP.
(2001) A barbourin-albumin fusion protein that

recombinant factor VIIa. Thromb. Res.

122 (Suppl. 4), S14-S19.
11. Weimer T, Wormsbacher W, Kronthaler U, LangW, Liebing U,
Schulte S. (2008) Prolonged in-vivo half-life of factor VIIa by
fusion to albumin. Thromb. Haemost. 99, 659-667.
12. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S.
(2009) Genetic fusion to albumin improves the pharmaco-
kinetic properties of factor IX. Thromb. Haemost. 102, 634-
644.
13. Schmidt SR. (2009) Fusion-proteins as biopharmaceuticals—
applications and challenges. Curr. Opin. Drug Discov. Devel.
12, 284-295.
14. Gao Z, Bai G, Chen J, Zhang Q, Pan, P, Bai F, et al. (2009)
Development, characterization, and evaluation of a fusion
protein of a novel glucagon-like peptide-1 (GLP-1) analog
and human serum albumin in Pichia pastoris. Biosci. Bio-
technol. Biochem. 73, 688-694.
15. Huang YS, Chen Z, Chen YQ, Ma GC, Shan JF, Liu W, et al.
(2008) Preparation and characterization of a novel exendin-4
human serum albumin fusion protein expressed in Pichia
pastoris. J. Pept. Sci. 14, 588-595.
16. Daly R, Hearn MT. (2005) Expression of heterologous proteins
in Pichia pastoris: a useful experimental tool in protein
engineering and production. J. Mol. Recognit. 18, 119-138.
17. Chen HH, Martin FL, Cataliotti A, Schirger JA, Burnett JC.
(2007) AlbuBNP (Cardeva), a novel recombinant human B-
type natriuretic peptide serum albumin fusion protein has
prolonged renal enhancing properties when compared to
human BNP. Circulation 116, II_284 [Abstract 1382].
18. Chen J-H, Zhang X-G, Jiang Y-T, Yan L-Y, Tang LO, Yin Y-W,
et al. (2010) Bioactivity and pharmacokinetics of two human
serum albumin-thymosin a 1-fusion proteins, rHSA-T a 1 and
rHSA-L-T a 1, expressed in recombinant Pichia pastoris. Can-
cer Immunol. Immunother. 59, 1335-1345.
19. Muller D, Karle A, Meissburger B, Hofig I, Stork R, Konter-
mann RE. (2007) Improved pharmacokinetics of recombinant
bispecific antibody molecules by fusion to human serum
albumin. J. Biol. Chem. 282, 12650-12660.
20. Dou W-F, Lei J-Y, Zhang L-F, Xu Z-H, Chen Y, Jin J. (2008)
Expression, purification, and characterization of recombinant
human serum albumin fusion protein with two human gluca-
gon-like peptide-1 mutants in Pichia pastoria. Protein Expr.
Purif. 61, 45-49.
21. Halpern W, Riccobene TA, Agostini H, Baker K, Stolow D, Gu
ML, et al. (2002) Albugranin, a recombinant human granulo-
cyte colony stimulating factor (G-CSF) genetically fused to

is slowly